Department of Cardiovascular Medicine (V.N., F.F., M.P., J.L., Y.X., E.L., A.L.), Mayo Clinic, Rochester, MN.
Department of Laboratory of Medicine and Pathology (E.M.F., M.P.A., M.C.B., R.J.S.), Mayo Clinic, Rochester, MN.
Hypertension. 2022 Aug;79(8):1814-1823. doi: 10.1161/HYPERTENSIONAHA.122.19247. Epub 2022 Jun 3.
Uric acid (UA) concentration within carotid plaque and its association with cerebrovascular events have not been detected or quantified. Systemically, serum UA is a marker of inflammation and risk factor for atherosclerosis. However, its association with carotid plaque instability and stroke pathogenesis remains unclear. In patients undergoing carotid endarterectomy, we aimed to determine whether UA is present differentially in symptomatic versus asymptomatic carotid plaques and whether serum UA is associated with cerebrovascular symptoms (stroke, transient ischemic attack, or amaurosis fugax).
Carotid atherosclerotic plaques were collected during carotid endarterectomy. The presence of UA was assessed using Gomori methenamine silver staining as well as anti-UA immunohistochemical staining and its quantity measured using an enzymatic colorimetric assay. Clinical information was obtained through a retrospective review of data.
UA was more commonly detected in symptomatic (n=23) compared with asymptomatic (n=9) carotid plaques by Gomori methenamine silver (20 [86.9%] versus 2 [22.2%]; =0.001) and anti-UA immunohistochemistry (16 [69.5%] versus 1 [11.1%]; =0.004). UA concentration was higher in symptomatic rather than asymptomatic plaques (25.1 [9.5] versus 17.9 [3.8] µg/g; =0.021). Before carotid endarterectomy, serum UA levels were higher in symptomatic (n=341) compared with asymptomatic (n=146) patients (5.9 [interquartile range, 4.6-6.9] mg/dL versus 5.2 [interquartile range, 4.6-6.2] mg/dL; =0.009).
The current study supports a potential role of UA as a potential tissue participant and a systemic biomarker in the pathogenesis of carotid atherosclerosis. UA may provide a mechanistic explanation for plaque instability and subsequent ischemic cerebrovascular events.
颈动脉斑块内尿酸(UA)浓度及其与脑血管事件的关系尚未被检测或量化。在系统水平上,血清 UA 是炎症的标志物和动脉粥样硬化的危险因素。然而,其与颈动脉斑块不稳定性和中风发病机制的关系仍不清楚。在接受颈动脉内膜切除术的患者中,我们旨在确定 UA 是否在有症状与无症状颈动脉斑块中存在差异,以及血清 UA 是否与脑血管症状(中风、短暂性脑缺血发作或一过性黑矇)相关。
在颈动脉内膜切除术中收集颈动脉粥样硬化斑块。使用 Gomori 六胺银染色以及抗 UA 免疫组织化学染色来评估 UA 的存在,并使用酶比色法测量其含量。通过回顾性数据分析获得临床信息。
Gomori 六胺银(20 [86.9%] 对 2 [22.2%];=0.001)和抗 UA 免疫组化(16 [69.5%] 对 1 [11.1%];=0.004)显示,UA 在有症状(n=23)的颈动脉斑块中比无症状(n=9)的更常见。有症状而非无症状斑块中的 UA 浓度更高(25.1 [9.5] 对 17.9 [3.8] µg/g;=0.021)。在颈动脉内膜切除术前,有症状(n=341)的患者血清 UA 水平高于无症状(n=146)的患者(5.9 [四分位距,4.6-6.9] mg/dL 对 5.2 [四分位距,4.6-6.2] mg/dL;=0.009)。
本研究支持 UA 作为颈动脉粥样硬化发病机制中的潜在组织参与者和系统性生物标志物的作用。UA 可能为斑块不稳定性和随后的缺血性脑血管事件提供一种机制解释。